AXTI AXT Inc.

AXT, Inc. Announces Fourth Quarter and Fiscal Year 2022 Financial Results

AXT, Inc. Announces Fourth Quarter and Fiscal Year 2022 Financial Results

FREMONT, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor substrates, today reported financial results for the fourth quarter and fiscal year, ended December 31, 2022.

Management Qualitative Comments

“2022 was a productive year in which we grew both our revenue and our profitability, and invested in innovations that pave the way for an exciting future,” said Morris Young, chief executive officer. “Though a softening of the macro environment has reset our growth trajectory, the trends that have driven our revenue, customer, and application expansion remain very much intact. We continue to see active development for technology advancement using our materials across consumer, communications infrastructure, data center, healthcare, automotive, and more. In addition, we have made significant progress this year in the development of next generation large diameter substrates for gallium arsenide and indium phosphide, which can enable a host of exciting new applications in our industry. As such, the fundamentals in our business are solid and we are looking ahead to our future with optimism.”

Fourth Quarter 2022 Results

In order to provide better clarity on its operational and financial results, AXT began reporting its financial results on both a GAAP and non-GAAP basis in the third quarter of 2021. Non-GAAP results exclude stock-based compensation expense. Investors can find GAAP to non-GAAP reconciliation tables in the financial statements in this earnings release.

  • Revenue for the fourth quarter of 2022 was $26.8 million, compared with $35.2 million in the third quarter of 2022 and $37.7 million for the fourth quarter of 2021.



  • GAAP gross margin was 32.1 percent of revenue for the fourth quarter of 2022, compared with 42.0 percent of revenue in the third quarter of 2022 and 32.2 percent for the fourth quarter of 2021.



  • Non-GAAP gross margin, after eliminating charges for stock-based compensation, was 32.5 percent of revenue for the fourth quarter of 2022, compared with 42.2 percent of revenue in the third quarter of 2022 and 32.4 percent for the fourth quarter of 2021.



  • GAAP operating expenses were $9.6 million in the fourth quarter of 2022. This compares with $10.2 million in the third quarter of 2022 and $9.1 million for the fourth quarter of 2021.  



  • Non-GAAP operating expenses were $9.0 million in the fourth quarter of 2022. This compares with $9.2 million in the third quarter of 2022 and $8.1 million for the fourth quarter of 2021.



  • GAAP operating profit/(loss) for the fourth quarter of 2022 was an operating loss of ($1.0) million, compared with an operating profit of $4.6 million in the third quarter of 2022 and an operating profit of $3.0 million for the fourth quarter of 2021.



  • Non-GAAP operating profit/(loss) for the fourth quarter of 2022 was an operating loss of ($0.3) million, compared with operating profit of $5.6 million in the third quarter of 2022 and an operating profit of $4.1 million for the fourth quarter of 2021.



  • Non-operating income and expense, taxes and minority interest for the fourth quarter of 2022 was a net gain of $2.3 million, compared with a net gain of $1.2 million in the third quarter of 2022 and a net loss of $0.1 million for the fourth quarter of 2021.



  • GAAP net income in the fourth quarter of 2022 was $1.3 million, or $0.03 per share, compared with net income of $5.8 million or $0.13 per share in the third quarter of 2022, and net income of $3.0 million or $0.07 per share for the fourth quarter of 2021.



  • Non-GAAP net income in the fourth quarter of 2022 was $2.1 million, or $0.05 per share, compared with net income of $6.8 million or $0.16 per share in the third quarter of 2022, and net income of $4.1 million or $0.09 per share for the fourth quarter of 2021.

Fiscal Year 2022 Results (January 1 to December 31, 2022)

  • Revenue for fiscal year 2022 was $141.1 million, compared with $137.4 million in fiscal year 2021.  



  • GAAP gross margin for fiscal year 2022 was 36.9 percent of revenue, up from 34.5 percent of revenue in fiscal year 2021.



  • Non-GAAP gross margin for fiscal year 2022 was 37.2 percent of revenue, up from 34.8 percent of revenue in fiscal year 2021.



  • GAAP operating expenses for fiscal year 2022 were $39.6 million, compared with $34.5 million in fiscal year 2021.



  • Non-GAAP operating expenses for fiscal year 2022 were $35.9 million, compared with $30.4 million in fiscal year 2021.



  • GAAP operating income for fiscal year 2022 was $12.6 million compared with $12.9 million in fiscal 2021.



  • Non-GAAP operating income for fiscal year 2022 was $16.6 million compared with $17.4 million in fiscal 2021.



  • GAAP net income for fiscal 2022 was $15.8 million, or $0.37 per share, compared with $14.6 million, or $0.34 per share for fiscal 2021.



  • Non-GAAP net income for fiscal 2022 was $19.8 million, or $0.46 per share, compared with $19.1 million, or $0.44 per share for fiscal 2021.

STAR Market Listing Update

On January 10, 2022, AXT announced that Beijing Tongmei Xtal Technology Co., Ltd. (“Tongmei”), its subsidiary in Beijing, China, submitted to the Shanghai Stock Exchange (the “SSE”) its application to list its shares in an initial public offering (the “IPO”) on the SSE’s Sci-Tech innovAtion boaRd (the “STAR Market”) and the application was accepted for review. Subsequently, Tongmei responded to several rounds of questions received from the SSE. On July 12, 2022, the SSE approved the listing of Tongmei’s shares in an IPO on the STAR Market. On August 1, 2022, the China Securities Regulatory Commission (the “CSRC”) accepted for review Tongmei’s IPO application. The STAR Market IPO remains subject to review and approval by the CSRC and other authorities. The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process. Subject to review and approval by the CSRC and other authorities, Tongmei hopes to accomplish this goal in the coming months. AXT has posted a brief summary of the plan and the process on its website at .

Conference Call

The company will host a conference call to discuss these results today at 1:30 p.m. PT. The conference call can be accessed at (888) 300-4150 (passcode 7175811). The call will also be simulcast at . Replays will be available at (800) 770-2030 (passcode 7175811) until March 2, 2023. Additional investor information can be accessed at  or by calling the company’s Investor Relations Department at (510) 438-4700.

About AXT, Inc.

AXT is a material science company that develops and manufactures high-performance compound and single element semiconductor substrate wafers comprising indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge). The company’s substrate wafers are used when a typical silicon substrate wafer cannot meet the performance requirements of a semiconductor or optoelectronic device. End markets include 5G infrastructure, data center connectivity (silicon photonics), passive optical networks, LED lighting, lasers, sensors, power amplifiers for wireless devices and satellite solar cells. AXT’s worldwide headquarters are in Fremont, California where the company maintains sales, administration and customer service functions. AXT has its Asia headquarters in Beijing, China and manufacturing facilities in three separate locations in China. In addition, as part of its supply chain strategy, the company has partial ownership in ten companies in China producing raw materials for its manufacturing process. For more information, see AXT’s website at .

Safe Harbor Statement

The foregoing paragraphs contain forward-looking statements within the meaning of the Federal securities laws, including, for example, statements regarding the timing and completion of the proposed listing of shares of Tongmei on the STAR Market. Additional examples of forward-looking statements include statements regarding the market demand for our products, our product mix, our growth prospects and opportunities for continued business expansion, including technology trends, new applications and the ramping of Tier-1 customers, our market opportunity, our ability to lead our industry, our relocation, our expectations with respect to our business prospects and financial results, including our gross margin performance, and our development of larger diameter substrates that we believe will enable the next generation of technology innovation across a number of end-markets. These forward-looking statements are based upon assumptions that are subject to uncertainties and factors relating to the company’s operations and business environment, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements contained in the foregoing discussion. These uncertainties and factors include but are not limited to: the requests for redemptions by private equity funds in China of investments in Tongmei, the administrative challenges in satisfying the requirements of various government agencies in China in connection with the listing of shares of Tongmei on the STAR Market, continued open access to companies to list shares on the STAR Market, investor enthusiasm for new listings of shares on the STAR Market and geopolitical tensions between China and the United States. Additional uncertainties and factors include, but are not limited to: the timing and receipt of significant orders; the cancellation of orders and return of product; emerging applications using chips or devices fabricated on our substrates; end-user acceptance of products containing chips or devices fabricated on our substrates; our ability to bring new products to market; product announcements by our competitors; the ability to control costs and improve efficiency; the ability to utilize our manufacturing capacity; product yields and their impact on gross margins; the relocation of manufacturing lines and ramping of production; possible factory shutdowns as a result of air pollution in China or COVID-19; COVID-19 or other outbreaks of a contagious disease; tariffs and other trade war issues; the financial performance of our partially owned supply chain companies; policies and regulations in China; and other factors as set forth in the company’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Each of these factors is difficult to predict and many are beyond the company’s control. The company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise.

FINANCIAL TABLES TO FOLLOW

AXT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share data)

 Three Months Ended  Year Ended
 December 31, December 31,
 2022 2021 2022 2021
            
Revenue$26,795  $37,732  $141,118  $137,393 
Cost of revenue 18,199   25,593   88,997   89,979 
Gross profit 8,596   12,139   52,121   47,414 
Operating expenses:           
Selling, general and administrative 5,935   6,348   25,654   24,189 
Research and development 3,662   2,757   13,913   10,328 
Total operating expenses 9,597   9,105   39,567   34,517 
Income (loss) from operations (1,001)  3,034   12,554   12,897 
Interest expense, net (401)  (158)  (1,071)  (213)
Equity in income of unconsolidated joint ventures 649   735   5,957   4,409 
Other income (expense), net 2,245   (389)  3,487   509 
Income before provision for (benefit from) income taxes 1,492   3,222   20,927   17,602 
Provision for (benefit from) income taxes (3)  (411)  2,185   1,093 
Net income 1,495   3,633   18,742   16,509 
Less: Net income attributable to noncontrolling interests and redeemable noncontrolling interests (154)  (668)  (2,931)  (1,934)
Net income attributable to AXT, Inc.$1,341  $2,965  $15,811  $14,575 
Net income attributable to AXT, Inc. per common share:           
Basic$0.03  $0.07  $0.37  $0.35 
Diluted$0.03  $0.07  $0.37  $0.34 
Weighted-average number of common shares outstanding:           
Basic 42,383   41,758   42,104   41,367 
Diluted 42,705   42,750   42,715   42,720 
                

AXT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands)

 December 31, December 31,
 2022 2021
      
ASSETS     
Current assets:     
Cash and cash equivalents$34,948  $36,763 
Restricted cash 6,400    
Short-term investments 9,339   5,419 
Accounts receivable, net 29,252   34,839 
Inventories 89,629   65,912 
Prepaid expenses and other current assets 13,977   17,252 
Total current assets 183,545   160,185 
Long-term investments 2,118   9,576 
Property, plant and equipment, net 161,017   142,415 
Operating lease right-of-use assets 1,761   2,324 
Other assets 21,631   17,941 
Total assets$370,072  $332,441 
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS’ EQUITY     
Current liabilities:     
Accounts payable$10,084  $16,649 
Accrued liabilities 18,164   17,057 
Short-term loan, related party    1,887 
Bank loans 47,078   12,229 
Total current liabilities 75,326   47,822 
Noncurrent operating lease liabilities 1,322   1,935 
Other long-term liabilities 3,678   2,453 
Total liabilities 80,326   52,210 
      
Redeemable noncontrolling interests 44,846   50,385 
      
Stockholders’ equity:     
Preferred stock 3,532   3,532 
Common stock 44   43 
Additional paid-in capital 235,308   231,622 
Accumulated deficit (14,159)  (29,970)
Accumulated other comprehensive income (loss) (3,118)  6,302 
Total AXT, Inc. stockholders’ equity 221,607   211,529 
Noncontrolling interests 23,293   18,317 
Total stockholders’ equity 244,900   229,846 
Total liabilities, redeemable noncontrolling interests and stockholders’ equity$370,072  $332,441 
        

AXT, INC.

Reconciliation of Statements of Operations Under GAAP and Non-GAAP

(Unaudited, in thousands)

 Three Months Ended  Year Ended
 December 31, December 31,
 2022 2021 2022 2021
GAAP gross profit$8,596  $12,139  $52,121  $47,414 
Stock-based compensation expense 102   105   379   368 
Non-GAAP gross profit$8,698  $12,244  $52,500  $47,782 
               
GAAP operating expenses$9,597  $9,105  $39,567  $34,517 
Stock-based compensation expense 643   983   3,627   4,151 
Non-GAAP operating expenses$8,954  $8,122  $35,940  $30,366 
               
GAAP income (loss) from operations$(1,001) $3,034  $12,554  $12,897 
Stock-based compensation expense 745   1,088   4,006   4,519 
Non-GAAP income (loss) from operations$(256) $4,122  $16,560  $17,416 
               
GAAP net income$1,341  $2,965  $15,811  $14,575 
Stock-based compensation expense 745   1,088   4,006   4,519 
Non-GAAP net income$2,086  $4,053  $19,817  $19,094 
               
GAAP net income per diluted share$0.03  $0.07  $0.37  $0.34 
Stock-based compensation expense per diluted share$0.02  $0.03  $0.09  $0.11 
Non-GAAP net income per diluted share$0.05  $0.09  $0.46  $0.44 
               
Shares used to compute diluted net income per share 42,705   42,750   42,715   42,720 
                



Contacts:
Gary Fischer

Chief Financial Officer

(510) 438-4700



Leslie Green

Green Communications Consulting, LLC

(650) 312-9060
 


EN
16/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AXT Inc.

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines | META, Anthropic, Xiaomi, Handsets

Rapidus: Reportedly secures ¥167.6B ($1.1B) private funding; 60 clients reportedly in talks with 10 receiving initial quotesView: Japan’s Rapidus has reportedly secured these private funds, which add to the ¥100B in government investment in Rapidus this year.The Japanese startup is targeting mass p

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch